Literature DB >> 9560247

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.

A Gualberto1, K Aldape, K Kozakiewicz, T D Tlsty.   

Abstract

Although it is well-established that p53 functions as a tumor suppressor gene, certain mutations exhibit gain-of-function activities that increase oncogenic transformation. We have found a common class of p53 missense mutation that exhibits a dominant, gain-of-function activity that generates genomic instability. Fibroblasts from Li-Fraumeni syndrome heterozygotes with such mutations generate polyploid cells when exposed to spindle depolymerizing agents. Expression of such mutant alleles in normal fibroblasts yields the same phenotype. This class of dominant, gain-of-function p53 mutation (p53(RSC), relaxed spindle checkpoint allele) does not require the transcriptional activation function of p53 for this behavior. Thus p53 mutations can contribute to progression of a cancer cell not only by absence of p53 tumor suppressor activity but also by the presence of an activity that promotes genetic instability.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9560247      PMCID: PMC20232          DOI: 10.1073/pnas.95.9.5166

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

Review 1.  Checkpoints: controls that ensure the order of cell cycle events.

Authors:  L H Hartwell; T A Weinert
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

2.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

3.  Rearrangement of the p53 gene in human osteogenic sarcomas.

Authors:  H Masuda; C Miller; H P Koeffler; H Battifora; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 4.  p53: oncogene or anti-oncogene?

Authors:  D P Lane; S Benchimol
Journal:  Genes Dev       Date:  1990-01       Impact factor: 11.361

Review 5.  Functional inactivation of genes by dominant negative mutations.

Authors:  I Herskowitz
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

6.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

7.  Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

Authors:  D Wolf; N Harris; V Rotter
Journal:  Cell       Date:  1984-08       Impact factor: 41.582

8.  Model for the genetic evolution of human solid tumors.

Authors:  S E Shackney; C A Smith; B W Miller; D R Burholt; K Murtha; H R Giles; D M Ketterer; A A Pollice
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

9.  p53 increases experimental metastatic capacity of murine carcinoma cells.

Authors:  J Pohl; N Goldfinger; A Radler-Pohl; V Rotter; V Schirrmacher
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

10.  A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.

Authors:  M Harvey; H Vogel; D Morris; A Bradley; A Bernstein; L A Donehower
Journal:  Nat Genet       Date:  1995-03       Impact factor: 38.330

View more
  60 in total

1.  Inhibition of T-cell acute lymphoblastic leukemia proliferation in vivo by re-expression of the p16INK4a tumor suppressor gene.

Authors:  K Schoppmeyer; P S Norris; M Haas
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1.

Authors:  Alonso Heredia; Charles Davis; Anthony Amoroso; Joyelle K Dominique; Nhut Le; Erin Klingebiel; Elise Reardon; Davide Zella; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

3.  Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.

Authors:  Byron Hann; Allan Balmain
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Altered centrosome structure is associated with abnormal mitoses in human breast tumors.

Authors:  W L Lingle; J L Salisbury
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 5.  Links between mutant p53 and genomic instability.

Authors:  Walter Hanel; Ute M Moll
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

Review 6.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

7.  p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

Authors:  C J Di Como; C Gaiddon; C Prives
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

8.  Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer.

Authors:  Dae-Sung Yoon; Robert P Wersto; Weibo Zhou; Francis J Chrest; Elizabeth S Garrett; Teag Kyu Kwon; Edward Gabrielson
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

9.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

10.  Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers.

Authors:  Akira Masuda; Ken Maeno; Taku Nakagawa; Hiroko Saito; Takashi Takahashi
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.